Clinical trial readout dates for Structure Therapeutics Inc., compiled from
ClinicalTrials.gov, alongside the SEC filings where results are announced.
Market cap$3.5B
Cash & investments$1.24B~9 quarters at last loss rate
Recent 8-K filings1latest 2026-11-09
Target dates already passed
These dates have elapsed; the company may have reported, or guidance may have shifted.
Phase 3Aleniglipron (GSBR-1290)
Type 2 Diabetes, obesity
October 24, 2025
Trial Planned
Cash position
Structure Therapeutics Inc. reported $1.24B in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-09). Its net loss for that quarter was $145M; at that rate the cash would last about 9 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.
Recent SEC filings
8-KResults of Operations — earnings, may carry pipeline updates